Sharemaestro company-news research for Generate Biomedicines, Inc. Common Stock (GENB), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Insufficient evidence
Company news sentiment
Latest GENB news and sentiment
Generate Biomedicines, Inc. Common Stock
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
No current company-news score
No company-specific headline in the last 30 days currently passes the date and relevance checks. The dash means no score; it is not a neutral observation.
Observed headline tone50/100
→
Published 30-day score50/100
Latest source headline
Top Generate Biomedicines (GENB) Competitors 2026
MarketBeat · 11 Oct 2026 04:10
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
Available information
20 current stories are mapped specifically to GENB.
Why there is no score
The stories agree, but freshness-weighted evidence is only 0.000.
Confidence is 0/100, below the threshold for a firm score.
—/100
News scoreNo qualifying directional evidence
0/100
Confidencethin evidence
0%/100
Company news20 company stories
100/100
Story agreement0/100 difference
News history
Daily score and story count over 30 days
14 Sep29 Sep13 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.0 after freshness weightingSource breadth0
0 independent publishersCompany relevance0
share tied directly to this companyFreshness25
recency-weighted evidenceAgreement100
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
No sufficiently fresh, directly relevant company news is available for a price comparison.
26 completed price weeks25 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202650USD 14.34+4.7%
02 Oct 202650USD 13.69-9.6%
25 Sep 202650USD 15.15-11.6%
18 Sep 202650USD 17.14+9.0%
11 Sep 202651USD 15.72-4.1%
04 Sep 202649USD 16.39+6.9%
28 Aug 202650USD 15.33-4.9%
21 Aug 202648USD 16.12+3.1%
Insufficient evidence
News subjects
What is shaping the score
Market update5016 stories · 80%
Analyst action561 stories · 5%
Guidance501 stories · 5%
Regulatory and legal501 stories · 5%
Earnings501 stories · 5%
Source mix
Where the evidence comes from
MarketBeat505 stories · 25%
TradingView504 stories · 20%
Simply Wall Street503 stories · 15%
Investing.com Canada562 stories · 10%
CarePlus VietNam502 stories · 10%
Market source501 stories · 5%
The Chronicle-Journal501 stories · 5%
Recurring subjects
Subjects appearing most often
Life Sciences10Financial Markets7Earnings5Technology4IPO1Finance1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
28 May50 neutral13 Oct 22:54
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 13 Oct 22:54 | 50 | +0 | 0/100 (0) | 19 (-1) | Insufficient |
| 11 Oct 23:59 | 50 | +0 | 0/100 (-15) | 20 (-4) | Insufficient |
| 06 Oct 23:59 | 50 | +0 | 15/100 (0) | 24 (+1) | Provisional |
| 05 Oct 23:59 | 50 | +0 | 15/100 (0) | 23 (+1) | Provisional |
| 02 Oct 23:59 | 50 | +0 | 15/100 (0) | 22 (+2) | Provisional |
| 01 Oct 23:59 | 50 | +0 | 15/100 (0) | 20 (+3) | Provisional |
| 27 Sep 23:59 | 50 | +0 | 15/100 (-1) | 17 (-8) | Provisional |
| 23 Sep 23:59 | 50 | +0 | 16/100 (0) | 25 (0) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 20 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
No directional evidence to attribute yet
Company news can still be read below. Influence bars appear when a current story qualifies for the directional score.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
Top Generate Biomedicines (GENB) Competitors 2026
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 11 Oct 2026 04:10
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 2.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Top Generate Biomedicines (GENB) Competitors 2026
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 06 Oct 2026 06:23
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Analyst actionNot used in direction
Generate Biomedicines stock rating reiterated at Buy by H.C. Wainwright on cancer trial progress
H.C. Wainwright has reiterated its Buy rating and $30.00 price target for Generate Biomedicines (NASDAQ:GENB) after the company announced first-patient dosing in a Phase 1 study for an ovarian cancer therapy. Despite an 8.2% decline in shares over the past week and an InvestingPro analysi…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
H.C. Wainwright has reiterated its Buy rating and $30.00 price target for Generate Biomedicines (NASDAQ:GENB) after the company announced first-patient dosing in a Phase 1 study for an ovarian cancer therapy. Despite an 8.2% decline in shares over the past week and an InvestingPro analysis suggesting slight overvaluation, the company maintains a strong balance sheet. The firm also recently raised its price target from $25 due to positive clinical trial data related to asthma.
- Published
- 05 Oct 2026 12:30
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.4d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
GuidanceNot used in direction
Generate Biomedicines (NasdaqGS:GENB) Stock Forecast & Analyst Predictions
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 05 Oct 2026 07:00
- News subject
- Guidance
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Generate Biomedicines, Inc. (GENB) stock price, news, quote and history
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 02 Oct 2026 17:23
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.2d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Book value per share of Generate Biomedicines, Inc. – BMV:GENB
This page provides financial information for Generate Biomedicines, Inc. (BMV:GENB), specifically focusing on its book value per share. The content appears to be a financial data snippet from TradingView, indicating that the market is closed for this stock.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This page provides financial information for Generate Biomedicines, Inc. (BMV:GENB), specifically focusing on its book value per share. The content appears to be a financial data snippet from TradingView, indicating that the market is closed for this stock.
- Published
- 02 Oct 2026 14:01
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.4d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Generate Biomedicines, Inc. - Common Stock (Nasdaq:GENB) Stock Quote
This article provides a detailed stock quote for Generate Biomedicines, Inc. (Nasdaq: GENB), including its current price, trading volume, and 52-week range. It also highlights recent news, performance metrics against major market indices, and frequently asked questions about the company's…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides a detailed stock quote for Generate Biomedicines, Inc. (Nasdaq: GENB), including its current price, trading volume, and 52-week range. It also highlights recent news, performance metrics against major market indices, and frequently asked questions about the company's stock.
- Published
- 02 Oct 2026 09:29
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsIPOLife SciencesTechnology
—Unscored
Market updateNot used in direction
Top Generate Biomedicines (GENB) Competitors 2026
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 01 Oct 2026 22:56
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.0d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Total equity of Generate Biomedicines, Inc. – BMV:GENB
This article provides financial information for Generate Biomedicines, Inc. (BMV:GENB) on TradingView, specifically focusing on the company's total equity. It notes that the Mexican Stock Exchange market for GENB is closed with no trades. The article is part of a larger financial data pla…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides financial information for Generate Biomedicines, Inc. (BMV:GENB) on TradingView, specifically focusing on the company's total equity. It notes that the Mexican Stock Exchange market for GENB is closed with no trades. The article is part of a larger financial data platform.
- Published
- 01 Oct 2026 19:55
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.1d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Cost of goods sold of Generate Biomedicines, Inc. – BMV:GENB
This article provides financial data for Generate Biomedicines, Inc. (BMV:GENB), specifically focusing on its cost of goods sold. The data is presented within the context of the Mexican Stock Exchange, indicating market status and offering an overview of the company's financials.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides financial data for Generate Biomedicines, Inc. (BMV:GENB), specifically focusing on its cost of goods sold. The data is presented within the context of the Mexican Stock Exchange, indicating market status and offering an overview of the company's financials.
- Published
- 01 Oct 2026 17:20
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.2d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
ETFs Investing in Generate Biomedicines, Inc. Stocks
This article lists various ETFs that include Generate Biomedicines, Inc. (GENB) stocks in their holdings. It provides detailed financial metrics for each ETF, such as market value, weight of GENB, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volu…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article lists various ETFs that include Generate Biomedicines, Inc. (GENB) stocks in their holdings. It provides detailed financial metrics for each ETF, such as market value, weight of GENB, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. The ETFs cover different investment strategies, including genomic revolution, U.S. tech leaders, medical breakthroughs, small cap growth, and biotech clinical trials.
- Published
- 01 Oct 2026 16:20
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.3d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Financial MarketsLife SciencesTechnology
—Unscored
Market updateNot used in direction
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
Roswell Park Comprehensive Cancer Center and Generate Biomedicines have initiated a first-in-human clinical trial for GB-5267, an "armored" CAR T-cell therapy targeting ovarian cancer. This innovative therapy, engineered with AI, aims to overcome limitations of traditional cell therapies …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Roswell Park Comprehensive Cancer Center and Generate Biomedicines have initiated a first-in-human clinical trial for GB-5267, an "armored" CAR T-cell therapy targeting ovarian cancer. This innovative therapy, engineered with AI, aims to overcome limitations of traditional cell therapies in solid tumors by enhancing T-cell potency, proliferation, and persistence in the suppressive tumor microenvironment. Notably, this trial avoids pre-infusion chemotherapy, offering a potentially less toxic treatment option for patients whose ovarian cancer has recurred or is resistant to platinum-based chemotherapy.
- Published
- 01 Oct 2026 10:54
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.5d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Life Sciences
—Unscored
Market updateNot used in direction
Generate Biomedicines (Nasdaq:GENB) - Stock Analysis
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 01 Oct 2026 07:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Regulatory and legalNot used in direction
An ovarian cancer trial tests cell therapy without chemotherapy beforehand. Its first patient has been dosed.
Generate Biomedicines (NASDAQ: GENB) and Roswell Park have dosed the first patient in a phase 1 clinical trial for GB-5267, an investigational CAR T-cell therapy for ovarian cancer. This AI-engineered therapy targets MUC16 and is notable for not requiring lymphodepletion (pre-infusion che…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Generate Biomedicines (NASDAQ: GENB) and Roswell Park have dosed the first patient in a phase 1 clinical trial for GB-5267, an investigational CAR T-cell therapy for ovarian cancer. This AI-engineered therapy targets MUC16 and is notable for not requiring lymphodepletion (pre-infusion chemotherapy), aiming to reduce side effects and improve patient outcomes. The trial will evaluate the safety and tolerability of GB-5267 in patients whose disease has returned or is resistant to platinum-based chemotherapy.
- Published
- 01 Oct 2026 07:00
- News subject
- Regulatory and legal
- Why this score
- Negative financial language
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life Sciences
—Unscored
Market updateNot used in direction
Top Generate Biomedicines (GENB) Competitors 2026
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 27 Sep 2026 20:27
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.1d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Generate Biomedicines at Bernstein healthcare forum: data, not models By Investing.com
Generate Biomedicines presented its AI-driven drug discovery platform at the Bernstein Healthcare Forum, emphasizing that proprietary biological data, rather than AI models alone, will be its main long-term advantage. CEO Mike Nally discussed the company's pipeline, including its lead Pha…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Generate Biomedicines presented its AI-driven drug discovery platform at the Bernstein Healthcare Forum, emphasizing that proprietary biological data, rather than AI models alone, will be its main long-term advantage. CEO Mike Nally discussed the company's pipeline, including its lead Phase III asthma drug (GB-0895) and a second clinical program (GB-4362) targeting peripheral neuropathy from cancer treatment. The company balances wholly-owned development with partnerships, aiming for capital efficiency and leveraging its accelerated experimental verification cycles to rapidly advance molecules.
- Published
- 23 Sep 2026 18:16
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.2d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Life SciencesTechnology
—Unscored
Market updateNot used in direction
Top Generate Biomedicines (GENB) Competitors 2026
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 22 Sep 2026 16:52
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.3d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Generate Biomedicines (NasdaqGS:GENB) Stock Price
Generate Biomedicines (NasdaqGS:GENB) is currently undervalued by 38.8% with a fair value of US$27, compared to its current price of US$16.52. The company, which utilizes an AI-driven generative protein platform for drug discovery, is focusing on its long-acting respiratory biologics and …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Generate Biomedicines (NasdaqGS:GENB) is currently undervalued by 38.8% with a fair value of US$27, compared to its current price of US$16.52. The company, which utilizes an AI-driven generative protein platform for drug discovery, is focusing on its long-acting respiratory biologics and oncology programs, including GB-0895 for asthma and GB-4362 as an MMAE neutralizer. Insider Frances Arnold recently announced an intention to sell 32k shares, while the company maintains a flawless balance sheet with low risk.
- Published
- 21 Sep 2026 18:16
- News subject
- Market update
- Why this score
- Positive valuation view
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 22.2d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife SciencesTechnology
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 17 Sep 2026 17:30
- News subject
- Earnings
- Why this score
- Positive market reaction, Large positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.2d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Generate Biomedicines (GENB) Slips 3.15% as Shares Test Support Near $15 - Sign of Weakness
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 17 Sep 2026 13:47
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.4d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
GENB news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 71 older GENB headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to GENB, but the headline and available text are not mainly about Generate Biomedicines, Inc. Common Stock. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of GENB sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.